Clinical trials
Urinary Bladder Cancer clinical trials
Below are recruiting urinary bladder cancer clinical trials, each written for real people, not researchers. We’re tracking 166 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06388720RecruitingPhase 2
Two chemotherapy drugs for bladder cancer after BCG
This study tests a combination of two chemotherapy drugs, mitomycin-C and gemcitabine, given directly into the bladder for people with high-risk bladder cancer that hasn't been controlled with BCG therapy. It's an option for those who can't or don't want to have their bladder removed.
Goyang-siAges 20 years+ - NCT05614739RecruitingPhase 1
Study of vepugratinib for cancers with FGFR3 gene changes
This study tests a new pill, vepugratinib, for people whose cancer has a specific change in a gene called FGFR3. The drug targets this gene change to try to slow or shrink the cancer, and may be an option if standard treatments have not worked.
Tucson, ArizonaAges 18 years+ - NCT05652023Recruiting
Ultrasound test to check bladder muscle problems in adults
This study tests a noninvasive ultrasound approach to assess bladder muscle function during routine bladder testing. You may be offered ultrasound measurements while you already need standard care, aiming to improve how bladder problems are evaluated.
Rochester, MinnesotaAges 18–90 - NCT05786716RecruitingPhase 2/Phase 3
Trastuzumab plus pertuzumab for HER2-mutated cancers
This trial tests whether combining trastuzumab and pertuzumab can treat cancers that have HER2 amplification or an activating HER2 mutation. It looks at people ages 12 and older, and may include both children/teens and adults, using the study drug based on their HER2 test results.
BelfastAges 12 years+ - NCT07277413RecruitingPhase 1
Study of IDE892 for advanced solid tumors with MTAP deletion
This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.
Goodyear, ArizonaAges 18 years+ - NCT07319923Recruiting
AI early warning system for prostate and bladder cancer in Beijing men
This trial is testing an AI-based early warning system to find prostate and bladder cancer earlier. It is for men over 50 living in Beijing who are willing to take part in the screening and follow-up process.
BeijingAges 18–85 - NCT07111364Recruiting
Ultrasound with AI to diagnose bladder tumors
This study uses ultrasound with AI to better diagnose bladder masses. It's for people who have a suspicious finding on a bladder ultrasound and are already planning to have surgery to treat it.
BeijingAges 18–85 - NCT07614594Recruiting
Urine Test to Detect Bladder and Kidney Cancer
This study tests whether a simple urine test can accurately identify cancer in the bladder, ureters (tubes between kidneys and bladder), or renal pelvis (part of the kidney). You would provide urine samples before your planned surgery, and researchers will compare the urine test results to your actual tissue diagnosis after surgery.
Zhengzhou, HenanAges 18 years+ - NCT05944237RecruitingPhase 1/Phase 2
Early trial for advanced cancers using HTL0039732
This is a Phase 1/2 study testing how well HTL0039732 works and is tolerated in people with advanced solid tumors that have not responded to standard treatments. It may help by offering a new treatment option and learning which cancer types and body markers respond best.
CambridgeAges 18 years+ - NCT06026189Recruiting
Reducing cystoscopy for blood in urine
This trial tests if we can safely skip a bladder camera test (cystoscopy) for people who have microscopic blood in their urine. If you meet certain criteria, you may not need the procedure.
RotterdamAges Any age - NCT03216525RecruitingPhase 3
Alvimopan vs placebo to reduce bowel slowdown after bladder surgery
This trial tests whether alvimopan, a medicine given around the time of bladder removal surgery, can help your bowels start working sooner after surgery compared with a placebo (inactive pill). It may help shorten recovery by reducing bowel-related side effects on an enhanced recovery plan.
Boston, MassachusettsAges 18–85 - NCT07726992RecruitingPhase 3
New drug plus BCG for high-risk bladder cancer
This study tests a new immunotherapy drug (SHR-1501) combined with standard BCG therapy for people with a specific type of early bladder cancer (papillary-only, high-risk). The goal is to see if the combination helps prevent cancer from returning better than BCG alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06709196RecruitingPhase 4
Targeted antibiotics to prevent infections after bladder removal
This trial tests if using a personalized antibiotic approach before surgery can reduce infections compared to the usual one-size-fits-all antibiotics. It focuses on people having their bladder removed (cystectomy) with a specific type of urinary diversion.
AalborgAges 18 years+ - NCT07495072Recruiting
Timing of Blad-Care during BCG therapy for bladder cancer
This trial tests whether giving Blad-Care early or later during BCG treatment changes outcomes for people with non-muscle-invasive bladder cancer. BCG is a standard therapy that uses a germ to help your immune system fight cancer, and Blad-Care is a device used in the bladder.
Seoul, Dongdaemun-guAges 19 years+ - NCT06186414RecruitingPhase 1
SIM0237 with or without BCG for bladder cancer
This trial tests a new drug, SIM0237, alone or with BCG, for people with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that did not respond to BCG treatment. The goal is to see if it is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06696794RecruitingPhase 3
Testing mitomycin before surgery for high-risk bladder cancer
This trial tests whether giving mitomycin directly into the bladder before surgery can help people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this approach is safe and effective at preventing cancer from coming back.
Wuhan, HubeiAges 18–75 - NCT06889623Recruiting
Chemotherapy right after surgery for high-risk bladder cancer
This trial tests whether giving chemotherapy immediately after surgery can help people with high-risk, non-muscle-invasive bladder cancer. It aims to reduce the chance of the cancer coming back.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07202845Recruiting
Predicting chemo response in bladder cancer with MRI
This trial uses special MRI scans to see how well bladder cancer responds to chemotherapy before surgery. It may help doctors know early if the treatment is working.
AsyutAges 18 years+ - NCT07202819Recruiting
Chemotherapy and MRI before bladder surgery
This study looks at how well MRI scans can detect bladder cancer after chemotherapy, before surgery to remove the bladder. It may help doctors know if the chemo is working.
Asyut, Asyut GovernorateAges 18 years+ - NCT06995677RecruitingPhase 2
Study of TYRA-300 for bladder cancer that has not spread into muscle
This trial tests a new pill, TYRA-300, for people with a certain type of early-stage bladder cancer that has a specific genetic change (FGFR3). The goal is to see if it can help by targeting the cancer cells and possibly avoiding more invasive treatments.
Homewood, AlabamaAges 18 years+ - NCT06971614RecruitingPhase 2
T3011 for bladder cancer not responding to standard treatments
This trial tests a drug called T3011 for a type of bladder cancer that hasn't responded to standard treatments like BCG or chemotherapy. It aims to see if T3011 can help shrink the cancer or keep it from growing, offering a new option for people who have limited choices.
Queen Creek, ArizonaAges 18 years+ - NCT06663137RecruitingPhase 2
Study of a new treatment for high-grade bladder cancer
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
RaananaAges 18–80 - NCT06567743RecruitingPhase 2
Study of a new virus therapy for high-risk bladder cancer
This trial tests a new virus-based medicine, cretostimogene grenadenorepvec, given directly into the bladder for people with high-risk non-muscle-invasive bladder cancer. It may help prevent the cancer from coming back, especially for those who have not had BCG treatment or whose cancer did not respond to BCG.
Gilbert, ArizonaAges 18 years+ - NCT05879653RecruitingPhase 2
Pembrolizumab, drug EV, and radiation for bladder cancer
This Phase 2 study tests how well pembrolizumab and an antibody-drug medicine (EV) given with bladder radiation work for non-metastatic bladder cancer that is mostly urothelial. It may help some people control the cancer without it spreading to other organs.
Kobe, HyōgoAges 18 years+
Hear when a new Urinary Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for urinary bladder cancer?
- Yes. Clin2 currently lists 166 recruiting urinary bladder cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a urinary bladder cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a urinary bladder cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.